369 related articles for article (PubMed ID: 27450182)
1. Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.
Towles JK; Clark RN; Wahlin MD; Uttamsingh V; Rettie AE; Jackson KD
Drug Metab Dispos; 2016 Oct; 44(10):1584-97. PubMed ID: 27450182
[TBL] [Abstract][Full Text] [Related]
2. Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.
Bissada JE; Truong V; Abouda AA; Wines KJ; Crouch RD; Jackson KD
Drug Metab Dispos; 2019 Nov; 47(11):1257-1269. PubMed ID: 31492693
[TBL] [Abstract][Full Text] [Related]
3. Interaction of lapatinib with cytochrome P450 3A5.
Chan EC; New LS; Chua TB; Yap CW; Ho HK; Nelson SD
Drug Metab Dispos; 2012 Jul; 40(7):1414-22. PubMed ID: 22511346
[TBL] [Abstract][Full Text] [Related]
4. Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib.
Amaya GM; Durandis R; Bourgeois DS; Perkins JA; Abouda AA; Wines KJ; Mohamud M; Starks SA; Daniels RN; Jackson KD
Chem Res Toxicol; 2018 Jul; 31(7):570-584. PubMed ID: 29847931
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
Teng WC; Oh JW; New LS; Wahlin MD; Nelson SD; Ho HK; Chan EC
Mol Pharmacol; 2010 Oct; 78(4):693-703. PubMed ID: 20624855
[TBL] [Abstract][Full Text] [Related]
6. Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.
Hardy KD; Wahlin MD; Papageorgiou I; Unadkat JD; Rettie AE; Nelson SD
Drug Metab Dispos; 2014 Jan; 42(1):162-71. PubMed ID: 24191259
[TBL] [Abstract][Full Text] [Related]
7. Interindividual Variability in Cytochrome P450 3A and 1A Activity Influences Sunitinib Metabolism and Bioactivation.
Burnham EA; Abouda AA; Bissada JE; Nardone-White DT; Beers JL; Lee J; Vergne MJ; Jackson KD
Chem Res Toxicol; 2022 May; 35(5):792-806. PubMed ID: 35484684
[TBL] [Abstract][Full Text] [Related]
8. Detoxication versus Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib.
Nardone-White DT; Bissada JE; Abouda AA; Jackson KD
Drug Metab Dispos; 2021 Mar; 49(3):233-244. PubMed ID: 33376146
[No Abstract] [Full Text] [Related]
9. Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation.
Zhu Y; Wang F; Li Q; Zhu M; Du A; Tang W; Chen W
Drug Metab Dispos; 2014 Feb; 42(2):245-9. PubMed ID: 24301608
[TBL] [Abstract][Full Text] [Related]
10. Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.
Takakusa H; Wahlin MD; Zhao C; Hanson KL; New LS; Chan EC; Nelson SD
Drug Metab Dispos; 2011 Jun; 39(6):1022-30. PubMed ID: 21363997
[TBL] [Abstract][Full Text] [Related]
11. The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine.
Topletz AR; Dennison JB; Barbuch RJ; Hadden CE; Hall SD; Renbarger JL
Drug Metab Dispos; 2013 Sep; 41(9):1651-61. PubMed ID: 23780963
[TBL] [Abstract][Full Text] [Related]
12. Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC-MS-Based Metabolomic Approaches.
Qin X; Wang Y; MacKenzie KR; Hakenjos JM; Chen S; Khalil SM; Jung SY; Young DW; Guo L; Li F
Chem Res Toxicol; 2023 Aug; 36(8):1427-1438. PubMed ID: 37531179
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes.
Kang P; Dalvie D; Smith E; Zhou S; Deese A
Drug Metab Dispos; 2007 Jul; 35(7):1081-8. PubMed ID: 17403914
[TBL] [Abstract][Full Text] [Related]
14. Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate.
Barbara JE; Kazmi F; Parkinson A; Buckley DB
Drug Metab Dispos; 2013 May; 41(5):1012-22. PubMed ID: 23404373
[TBL] [Abstract][Full Text] [Related]
15. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
[TBL] [Abstract][Full Text] [Related]
16. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4.
Wen B; Chen Y; Fitch WL
Drug Metab Dispos; 2009 Jul; 37(7):1557-62. PubMed ID: 19364830
[TBL] [Abstract][Full Text] [Related]
17. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
[TBL] [Abstract][Full Text] [Related]
18. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
20. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4.
Gallagher EP; Kunze KL; Stapleton PL; Eaton DL
Toxicol Appl Pharmacol; 1996 Dec; 141(2):595-606. PubMed ID: 8975785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
